GoodRx Holdings, Inc. (NASDAQ:GDRX) Shares Sold by Renaissance Technologies LLC

Posted by on Mar 7th, 2023

Renaissance Technologies LLC lowered its position in shares of GoodRx Holdings, Inc. (NASDAQ:GDRX – Get Rating) by 31.6% during the third quarter, according to the company in its most recent Form 13F filing with the SEC. The fund owned 2,221,622 shares of the company’s stock after selling 1,024,000 shares during the quarter. Renaissance Technologies LLC owned approximately 0.56% of GoodRx worth $10,375,000 as of its most recent filing with the SEC.

A number of other large investors also recently bought and sold shares of the stock. Northwestern Mutual Wealth Management Co. raised its stake in shares of GoodRx by 1,233.2% in the 2nd quarter. Northwestern Mutual Wealth Management Co. now owns 5,066 shares of the company’s stock valued at $30,000 after acquiring an additional 4,686 shares during the period. Levin Capital Strategies L.P. acquired a new position in GoodRx during the 3rd quarter valued at about $47,000. Victory Capital Management Inc. bought a new stake in shares of GoodRx during the 2nd quarter worth about $59,000. Apollon Wealth Management LLC bought a new stake in shares of GoodRx in the 2nd quarter worth approximately $60,000. Finally, Delphia USA Inc. bought a new stake in shares of GoodRx in the 1st quarter worth approximately $199,000. Hedge funds and other institutional investors own 35.22% of the company’s stock.

Analyst Upgrades and Downgrades

Several research analysts have recently weighed in on the stock. The Goldman Sachs Group dropped their target price on shares of GoodRx from $8.00 to $7.00 and set a “neutral” rating on the stock in a research report on Wednesday, March 1st. DA Davidson lowered their price objective on shares of GoodRx to $5.00 in a research report on Tuesday, November 15th. Wells Fargo & Company boosted their price objective on shares of GoodRx from $5.50 to $6.00 and gave the company an “equal weight” rating in a research report on Wednesday, March 1st. Morgan Stanley lowered their price objective on shares of GoodRx from $10.00 to $6.00 and set an “equal weight” rating on the stock in a research report on Wednesday, November 9th. Finally, Cowen lowered their price objective on shares of GoodRx to $6.50 in a research report on Wednesday, November 16th. Thirteen analysts have rated the stock with a hold rating and four have given a buy rating to the stock. Based on data from MarketBeat, the company has an average rating of “Hold” and an average price target of $7.92.

GoodRx Stock Performance

Shares of NASDAQ:GDRX opened at $5.52 on Tuesday. The company has a market capitalization of $2.19 billion, a price-to-earnings ratio of -78.85, a P/E/G ratio of 12.41 and a beta of 0.84. The firm’s 50 day simple moving average is $5.24 and its 200 day simple moving average is $5.25. The company has a debt-to-equity ratio of 0.80, a current ratio of 12.05 and a quick ratio of 12.05. GoodRx Holdings, Inc. has a fifty-two week low of $3.82 and a fifty-two week high of $20.59.

GoodRx Company Profile

(Get Rating)

GoodRx Holdings, Inc, through its subsidiaries, offers information and tools that enable consumers to compare prices and save on their prescription drug purchases in the United States. The company operates a price comparison platform that provides consumers with curated, geographically relevant prescription pricing, and access to negotiated prices through GoodRx codes that are used to save money on prescriptions across the United States.

See Also

Institutional Ownership by Quarter for GoodRx (NASDAQ:GDRX)

Receive News & Ratings for GoodRx Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for GoodRx and related companies with MarketBeat.com's FREE daily email newsletter.